The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

The latest announcement is out from Merck & Company ( (MRK) ).

Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...

Prescribing information for oseltamivir carries warnings about abnormal behavior in kids with flu based on case reports. Concerns about possible side effects may contribute to oseltamivir being ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

The global infectious disease treatment market is projected to grow from $72.5 billion in 2025 to $101 billion by 2030, with ...

The health and human services secretary and noted vaccine skeptic named a new panel to provide the guidance often used by ...

Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, ...

The Moderna layoffs are aimed at cutting costs amid declining vaccine sales and a shifting regulatory landscape.